Hasmeena Kathuria

Dr. Hasmeena Kathuria

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
FLFrank T. Leone
Frank T. Leone
YZYuqing Zhang
Yuqing Zhang
SESarah Evers-Casey
Sarah Evers-Casey
AEA. Eden Evins
A. Eden Evins
MEMichelle N. Eakin
Michelle N. Eakin
HFHarold J. Farber
Harold J. Farber
Background: Current tobacco treatment guidelines have established the efficacy of available interventions, but they do not provide detailed guidance for common implementation questions frequently faced in the clinic. An evidence-based guideline was created that addresses several pharmacotherapy-initiation questions that routinely confront treatment teams. Methods: Individuals with diverse expertise related to smoking cessation were empaneled to prioritize questions and outcomes important to clinicians. An evidence-synthesis team conducted systematic reviews, which informed recommendations to answer the questions. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach was used to rate the certainty in the estimated effects and the strength of recommendations. Results: The guideline panel formulated five strong recommendations and two conditional recommendations regarding pharmacotherapy choices. Strong recommendations include using varenicline rather than a nicotine patch, using varenicline rather than bupropion, using varenicline rather than a nicotine patch in adults with a comorbid psychiatric condition, initiating varenicline in adults even if they are unready to quit, and using controller therapy for an extended treatment duration greater than 12 weeks. Conditional recommendations include combining a nicotine patch with varenicline rather than using varenicline alone and using varenicline rather than electronic cigarettes. Conclusions: Seven recommendations are provided, which represent simple practice changes that are likely to increase the effectiveness of tobacco-dependence pharmacotherapy.

1 June 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KBKimberly A. Barker
Kimberly A. Barker
NENeelou S. Etesami
Neelou S. Etesami
ASAnukul Shenoy
Anukul Shenoy
EAEmad I. Arafa
Emad I. Arafa
CACarolina Lyon de Ana
Carolina Lyon de Ana
JMJoseph P. Mizgerd
Joseph P. Mizgerd
Lung-resident memory B cells (BRM cells) are elicited after influenza infections of mice, but connections to other pathogens and hosts — as well as their functional significance — have yet to be determined. We postulate that BRM cells are core components of lung immunity. To test this, we examined whether lung BRM cells are elicited by the respiratory pathogen pneumococcus, are present in humans, and are important in pneumonia defense. Lungs of mice that had recovered from pneumococcal infections did not contain organized tertiary lymphoid organs, but did have plasma cells and noncirculating memory B cells. The latter expressed distinctive surface markers (including CD69, PD-L2, CD80, and CD73) and were poised to secrete antibodies upon stimulation. Human lungs also contained B cells with a resident memory phenotype. In mice recovered from pneumococcal pneumonia, depletion of PD-L2+ B cells, including lung BRM cells, diminished bacterial clearance and the level of pneumococcus-reactive antibodies in the lung. These data define lung BRM cells as a common feature of pathogen-experienced lungs and provide direct evidence of a role for these cells in pulmonary antibacterial immunity.

5 April 2020 in Journal of Intensive Care
Verified
Journal Article
Open access
PDF file
HKHasmeena Kathuria
Hasmeena Kathuria
HHHelen M. Hollingsworth
Helen M. Hollingsworth
RVRajendran Vilvendhan
Rajendran Vilvendhan
CRChristine Reardon
Christine Reardon
It is estimated that 5–14% of patients presenting with hemoptysis will have life-threatening hemoptysis, with a reported mortality rate between 9 and 38%. This manuscript provides a comprehensive literature review on life-threatening hemoptysis, including the etiology and mechanisms, initial stabilization, and management of patients. There is no consensus on the optimal diagnostic approach to life-threatening hemoptysis, so we present a practical approach to utilizing chest radiography, computed tomography, and bronchoscopy, alone or in combination, to localize the bleeding site depending on patient stability. The role of angiography and embolization as well as bronchoscopic and surgical techniques for the management of life-threatening hemoptysis is reviewed. Through case presentation and flow diagram, an overview is provided on how to systematically evaluate and treat the bronchial arteries, which are responsible for hemoptysis in 90% of cases. Treatment options for recurrent hemoptysis and definitive management are discussed, highlighting the role of bronchial artery embolization for recurrent hemoptysis.

21 February 2018 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
RWRenda Soylemez Wiener
Renda Soylemez Wiener
EKElisa Koppelman
Elisa Koppelman
RBRendelle Bolton
Rendelle Bolton
KLKaren E. Lasser
Karen E. Lasser
BBBelinda Borrelli
Belinda Borrelli
HKHasmeena Kathuria
Hasmeena Kathuria

1 April 2019 in Preventive Medicine
Verified
Journal Article
Closed access
JIJonathan M. Iaccarino
Jonathan M. Iaccarino
CDCelina Duran
Celina Duran
CSChristopher G. Slatore
Christopher G. Slatore
RWRenda Soylemez Wiener
Renda Soylemez Wiener
HKHasmeena Kathuria
Hasmeena Kathuria

26 September 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HKHasmeena Kathuria
Hasmeena Kathuria
GMGuetchyn Millien
Guetchyn Millien
LMLiam McNally
Liam McNally
AGAdam C. Gower
Adam C. Gower
JTJean-Bosco Tagne
Jean-Bosco Tagne
MRMaria I. Ramirez
Maria I. Ramirez
The function of most long noncoding RNAs (lncRNAs) is unknown. However, recent studies reveal important roles of lncRNAs in regulating cancer-related pathways. Human antisense lncRNA-NKX2-1-AS1 partially overlaps the NKX2-1/TTF1 gene within chromosomal region 14q13.3. Amplification of this region and/or differential expression of genes therein are associated with cancer progression. Herein we show higher levels of NKX2-AS1 and NKX2-1 in lung adenocarcinomas relative to non-tumor controls but no correlation between NKX2-1-AS1 and NKX2-1 levels across specimens, or with amplification of the 14q13.3 region, suggesting that NKX2-1-AS1 and NKX2-1 are independently regulated. Loss-and-gain of function experiments showed that NKX2-1-AS1 does not regulate NKX2-1 expression, or nearby genes, but controls genes in trans. Genes up-regulated by NKX2-1-AS1-knockdown belong to cell adhesion and PD-L1/PD-1 checkpoint pathways. NKX2-1-AS1 negatively regulates endogenous CD274/PD-L1, a known target of NKX2-1, and the transcriptional activity of -1kb-CD274 promoter-reporter construct. Furthermore, NKX2-1-AS1 interferes with NKX2-1 protein binding to the CD274-promoter, likely by NKX2-1 protein-NKX2-1-AS1 interactions. Finally, NKX2-1-AS1 negatively regulates cell migration and wound healing, but not proliferation or apoptosis. These findings support potential roles of NKX2-1-AS1 in limiting motility and immune system evasion of lung carcinoma cells, highlighting a novel mechanism that may influence tumorigenic capabilities of lung epithelial cells.